Process for multi-analyses of rare cells extracted or isolated from biological samples through filtration

Patent metadata

Field	Value
Publication number	US-2020264166-A1
Application number	US-202016746443-A
Country	US
Kind code	A1
Filing date	Jan 17, 2020
Priority date	May 24, 2012
Publication date	Aug 20, 2020
Grant date	—

Abstract

A process for isolating or extracting rare cells from a biological sample comprising filtering a biological sample, which may be treated or diluted, through a filter that has a pore size, pore density or other physical properties that retain rare cells, but which permits other kinds of cells to pass through the filter. This process also comprises multiple analyses performed on rare cells after their extraction or isolation by filtration to diagnostically identify the presence of rare cells in a biological sample and to use their diagnostic identification and molecular characterization for diagnostic purposes such as for early diagnosis of diseases, namely for early diagnosis of cancer and to select, guide, monitor treatments and in particular to select targeted treatments and to monitor the response and/or resistance to them. A kit comprising tools, equipment and/or reagents to accomplish both the filtration step and various kinds of multiple analyses performed after isolation and extraction of the rare cells by filtration.

First claim

1 . A process for identifying, diagnosing, or providing a prognosis for a condition, disorder or disease associated with rare cells comprising:
(a) isolating or extracting rare cells by passing a biological sample through a filter and recovering the isolated rare cells on the filter; wherein the filter has a pore size, pore density or other physical characteristics that retain rare cells but which permit passage of other kinds of cells; (b) determining the cytomorphology of the isolated or extracted rare cells, and/or immunolabeling the isolated rare cells, and/or performing molecular analysis on the isolated rare cells; and (c) identifying, diagnosing, or providing a prognosis for a condition, disorder or disease and/or a stage of a condition, disorder or disease associated with the rare cells presence and/or number and/or characteristics based on the cytomorphology, and/or immunolabeling, and/or molecular analysis of the isolated or extracted rare cells.

2 - 20 : (canceled)

Assignees

• Rarecells Sas
• Univ Nice Sophia Antipolis
• Centre Hospitalier Univ De Nice
• Univ Paris Descartes
• Assist Publique-Hopitaux De Paris (Ap-Hp)
• Institut National De La Sante Et De La Rech Medicale (Inserm)

Inventors

• Paterlini-Brechot Patrizia
• Hofman Paul
• Laget Sophie Marie Genevieve
• Capiod Thierry

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5091 Primary

  for testing the pathological state of an organism · CPC title

• G01N33/554

  the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells · CPC title

• C12Q1/6876

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

• G01N2800/7028

  Cancer · CPC title